Penetration of target areas in the rat by liposome-associated bleomycin, glucose oxidase and insulin  by Dapergolas, Gerry et al.
Volume 63, number 2 FEBS LETTERS April 1976 
PENETRATION OF TARGET AREAS 1N THE RAT BY LIPOSOME-ASSOCIATED 
BLEOMYCIN, GLUCOSE OXIDASE AND INSULIN 
Gerry DAPERGOLAS, E. Diane NEERUNJUN and Gregory GREGORIADIS* 
Division of Clinical Investigation, Clinical Research Centre, Watford Road, Harrow, Middx. HA1 3UJ, England 
Received 16 January 1976 
1. Introduction 
The versatile role of liposomes as carriers of 
pharmacologically active agents is becoming increasingly 
apparent [1 ]. A wide variety of liposome-associated 
enzymes, drugs and other agents has been successfully 
applied in model systems for enzyme replacement 
therapy [2-4],  cancer chemotherapy [5-7],  heavy 
metal detoxification [8], prevention of viral 
infections [9] and also as immunological djuvants 
[10,11 ], interferon inducers [12] and diagnostic 
agents [13]. In addition, liposomes have been used 
for the introduction i to cells of agents which, 
normally, have no intracellular access [14,15 ]. 
Although it is now possible to increase selective 
uptake of liposomes by target cells [ 16], accessibility 
to these in vivo through capillary and other anatomical 
barriers can be limited by the size, charge and lipid 
composition of liposomes. 
In the present report we have attempted to 
establish conditions for the passage of liposome- 
associated agents into areas of the body which 
liposomes, depending on the route of administration, 
can either each only to a small extent or fail to 
enter altogether. As model target areas we have chosen: 
(a) malignant tissues approached by the intravenous 
route, (b) liver approached by the intraperitoneal or 
intramuscular route and (c) circulating blood 
approached by the intragastric route. In the latter 
case agents transported into the blood are expected to 
either exert heir effect locally or reach, and act in, 
other areas. 
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2. Materials and methods 
Bovine brain phosphatidyl inositol (sodium salt) 
was purchased from Lipid Products, Nr. Redhill, 
Surrey, England. The source and grades of all other 
lipids used have been described elsewhere [2]. 111In- 
labelled bleomycin (1.1 mCi//ag), 125 I-labelled insulin 
(> 50/iCi//~g) and 12Sl-labelled polyvinyl-pyrrolidone 
(50/~Ci/mg, average mol. wt. 3 -4  X 104) were from 
The Radiochemical Centre, Amersham, Bucks., England~ 
Aspergilus niger, glucose oxidase (grade II) from 
Boehringer, Mannheim, W. Germany, and insulin BP 
(80 units/ml) from Weddel Pharmaceuticals Ltd., 
London, England. Entrapment of a tracer of 111In- 
labelled bleomycin (2.5 mCi) and of ~2SI-labelled 
polyvinyl-pyrrolidone (100/aCi), of 200 mg glucose 
oxidase mixed with a tracer (0.4/aCi) of 12SI-labelled 
[17] glucose oxidase and of 160 units insulin mixed 
with 1/aCi 12SI-labelled insulin was carried out [16,18] 
in liposomes composed of egg lecithin and cholesterol 
(neutral, molar ratio 7:2) or the same supplemented 
with phosphatidic acid (negative) or stearylamine 
(positive, molar ratio 7:2:1). Liposomes were 
centrifuged at 100 000 g for 30 min or sonicated, 
when appropriate, for up to 20 min. Judging from 
radioactivity measurements, more than 60% of 
bleomycin was associated with negative liposomes 
and up to 5% of polyvinyl-pyrrolidone with negative, 
positive or neutral liposomes, 48% of glucose oxidase 
with negative liposomes and 20% of insulin with 
negative or positive liposomes. In some experiments 
insulin was associated (more than 90% of the 160 
units used) with liposomes prepared [19] from 6 mg 
phosphatidyl inositol. In other experiments a socia- 
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tion of glucose oxidase (52% of the 200 mg used) and 
of polyvinylpyrrolidone (5% of the tracer used) was 
carried out [18] in liposomes prepared with 20 and 
10 mg phosphatidyl inositol respectively. With both 
insulin and glucose oxidase, association with this 
lipid led to the formation of a precipitate which 
could not clear upon sonication (2 rain) and liposome- 
associated material was separated by centrifugation as 
above. Similarly sonicated free glucose oxidase and 
insulin could reduce blood glucose levels after 
intravenous injection into rats of 1 mg and 0.1 unit 
respectively and served as controls. 
Tumour-bearing animals were prepared by the 
implantation of 2 X 106 6C HED cells per animal in 
the intrascapular ea of C3 H mice and of 1 cm 3 
Met 'A'  malignant tissue per animal in the left kidney 
of Balb C mice. Eight (C3H) and eleven (Balb C) 
days later mice were injected in their tail vein with 
rain-labelled bleomycin, free (2 X 106 c.p.m.) or 
entrapped in negative gg lecithin liposomes (2 .5-3 .0  
mg lipid) sonicated for 0.5 min (1.5 X 106 c.p.m.) or 
20 min (2.4 X 106 c.p.m.). All mice were killed 
24-48  h after treatment and radioactivity, which was 
by then completely removed from the blood, was 
measured in the liver and tumour tissue. Male adult 
Sprague-Dawley rats weighing 100-150 g were 
injected intraperitoneally, or intramuscularly into 
the left thigh, with lZSI-labelled polyvinyl- 
pyrrolidone free (4 X 10s-7  X l0 s c.p.m.) or 
entrapped in negative gg lecithin liposomes 
(unsonicated or sonicated for 1 min, 2 X 105-3 X l0 s 
c.p.m., 6 .5-8.0 mg lipid). Rats were killed at time 
intervals and radioactivity measured in the blood 
and liver. Intragastric administration of 12SI-labelled 
polyvinylpyrrolidone (3 × l0 s 1.1 X 106 c.p.m.), 
glucose oxidase (175 mg/kg body weight) and insulin 
(480 units/kg body weight) in their free or liposome- 
associated form was performed in similar rats under 
light ether anaesthesia. Animals treated with poly- 
vinylpyrrolidone were kept in metabolic ages, killed 
at time intervals and radioactivity measured in the 
blood, liver 24 h homogenised faeces and 24 h urine. 
In animals treated with glucose oxidase and insulin, 
blood samples obtained from their tail vein 
immediately before and at time intervals after 
treatment, were analysed for glucose [20]. 
3. Results and discussion 
To accurately ascertain the extent to which lipo- 
somes can transport agents into tissues we adopted an 
approach which limits to a minimum any cell- l ipo- 
somal agent association other than that mediated by 
the liposome carrier. To this end we employed 
111 In-labelled bleomycin, a cytotoxic drug used in 
cancer chemotherapy, and lZSI-labelled polyvinyl- 
pyrrolidone both of which penetrate tissues poorly. 
When given in the entrapped form, these agents 
remain associated with the carrier in the circulation 
Table 1 
Uptake of radioactivity by tissues of mice injected with free and liposome-entrapped lnln-labelled bleomycin 
Uptake by tissues (% + S.D. of dose per g tissue) 
Liver Tumour 
Strain Implanted Free Sonicated Sonicated Free Sonicated Sonicated 
of tumour liposomes liposomes liposomes liposomes 
mice (0.5 rain) (20 min) (0.5 rain) (20 rain) 
C3H 6CallED 1.18-+ 0.25 32.8+- 3.1 25.6-+ 1.21 1.81+ 0.47 3.92-+0.51 6.82+ 0.94 
Balb C Meth 'A' 1.36 + 0.14 48.0 -+ 7.1 19.0 -+ 4.5 0.99 -+ 0.39 2.38 ± 0.69 6.49 -+ 1.39 
236 
6C3HED cells were implanted in the intrascapular rea of 24 C3H mice and Meth 'A' malignant tissue in the left 
kidney of 24 Balb C mice. Eight (Call) and 11 (Balb C) days later mice were injected in their tail vein with 
lnln-labelled Neomycin, free (8 mice) or entrapped in egg lecithin negative liposomes sonicated for 0.5 or 20 
rain(8 mice each). All mice were killed 24-48 h after treatment. Differences in liver or tumour values between 
any of two groups in each of the two strains of mice were statistically significant (P < 0.001-0.05). 
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and their radiolabels persist in the site to which the 
agents are eventually transported by the carrier ([ 16] 
and our unpublished observations). 
Uptake of radioactivity by the liver and turnout 
tissue of mice injected with 111 In-labelled bleomycin 
was highest when the liposome-associated drug was 
used (table 1). Further, uptake by tumours was 
greater for the smaller liposomes (20 min sonication) 
implying increased penetration of the vascular 
tumour barrier. In contrast, hepatic localisation of 
such liposomes was less pronounced than that of larger 
size liposomes (0.5 rain sonication) (table 1) probably 
because of the decreased rate of elimination of small 
liposomes from the circulation [21 ] which allows 
them longer contact with, and uptake by, other areas 
in the body (e.g. tumour tissue). 
Intraperitoneal dministration of 12SI-labelled 
polyvinylpyrrolidone was followed, as evidenced by 
the increased hepatic values eventually attained 
(table 2), by the entrance of this agent into the 
blood in its entrapped form. Indeed, penetration of 
intact liposomes through the vascular membranes of 
the peritoneum into the circulation was possible for 
both large unsonicated and smaller sonicated liposomes 
each of which was cleared from the blood and taken 
up by the liver at a rate proportional to its size [21] 
(table 2). Following intramuscular injection, however, 
entrance into the blood of entrapped ~zSI-labelled 
polyvinylpyrrolidone did depend on the size of the 
carrier. Thus, small liposomes appeared to reach the 
circulation and subsequently the liver while large 
unsonicated ones could not be traced in the blood or 
in the liver at 3 and 24 h (table 2). These liposomes 
were most probably incapable of transcapillary passage 
and were rapidly degraded in the site of injection with 
polyvinylpyrrolidone b ing slowly released into the 
blood and the lymphatics [22]. 
After intragastric administration of 12s I-labelled 
polyvinylpyrrolidone more than 98% of the radio- 
activity was recovered in the faeces in a non-dialysable 
form within 24 h and liver levels were very low 
(0.07 +- 0.02% of the dose per organ, 6 rats) at all 
time intervals. With polyvinylpyrrolidone entrapped 
in neutral, negative and positive sonicated (1.5 min) 
liposomes (including phosphatidyl inositol liposomes) 
there was a small (and similar) increase in hepatic uptake 
in all animals that received various liposomes and values 
were pooled (0.17 -+ 0.02%, P < 0.001, 16 rats). Oral 
pretreatment of rats with cholestearylamine (2.5 g/kg 
body weight) which neutralises bile salts did not 
improve hepatic uptake. 
Glucose oxidase, which, when given intravenously 
into rats (5 mg/kg body weight) was found to decrease 
blood glucose levels by more than 90% in 15 rain, had 
only a minimal effect over a 24 h period when given 
intragastrically (175 mg/kg) in its free from (fig. 1) or 
Table 2 
Uptake of radioactivity by the liver of rats injected with free and liposome-entrapped 
~2SI-labelled polyvinylpyrrolidone 
Polyvinylpyrrolidone 
Intraperitoneal injection Intramuscular injection 
Plasma Liver Plasma Liver 
Free, 3 h 31.4, 31.2 3.4, 2.4 14.8, 12.8 1.0, 0.8 
24h " 16.2,16.3 7.1, 6.7 7.5,11.0 3.6, 5.1 
Unsonicated liposomes, 3 h 5.2, 7.0 22.2, 23.1 1.6, 1.0 0.3, 0.2 
24 h 3.6, 3.0 29.2, 34.6 2.2, 2.0 2.3, 0.8 
Sonicated liposomes, 3 h 41.3, 34.3 14.5, 15.8 14.3, 12.0 2.4, 2.6 
24 h 22.5, 23.1 25.9, 23.5 18.0, 18.8 8.6, 11.3 
24 rats were inj ected intraperitoneally (12) and intramuscularly (12 ) with 12 s I-labelled p oly- 
vinylpyrrolidone, free or entrapped in unsonicated or sonicated (1 min) egg lecithin negative 
liposomes and killed in pairs 3 and 24 h later. Values in the total liver (corrected for blood con- 
tamination [1 ] and estimated [1 ] total plasma from individual rats are expressed as % of the 
injected ose. 
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inositol iposomes devoid of insulin had no effect. A 
similar, but of unspecified potency, preparation of 
liposomal insulin has been claimed to produce hypo- 
glycaemic shock in mice [19]. 
It appears that association of glucose oxidase and 
insulin with phosphatidyl inositol offers some protec- 
tion to these agents from inactivation i the gut and 
at the same time facilitates their transport into the 
blood where glucose oxidase and insulin exert their 
effect on glucose in their respective fashion. It is not 
clear as yet whether entrance into the circulation of 
these two proteins is mediated via intact liposomes 
as is probably the case for the small proportion of 
polyvinylpyrrolidone. In contrast to the latter, glucose 
oxidase and insulin seem to interact with phosphatidyl 
inositol iposomes (see Materials and methods) and it 
is possible that in spite of liposome disorganisation in 
the gut expected to occur in the presence of bile salts 
and phospholipases, lipid-protein complexes enter the 
portal circulation through the mucous membrane of 
the intestines or reach the peripheral circulation 
through the lymphatic pathways of the gut. 
Fig.1. Blood glucose in rats given intragastrically free or 
liposome-associated insulin and glucose oxidase. 31_rats were 
given intragastrically insulin (35 units), free (7, solid circles) 
or associated with phosphatidyl inositol iposomes (1.8 mg 
lipid) (7, solid triangles); glucose oxidase (25 mg) free 
(7, solid circles) or associated with phosphatidyl inositol 
liposomes (5.0 mg lipid) (7, solid triangles); phosphatidyl 
inositol iposomes (5.0 mg lipid) only (3, empty triangles). 
Values are expressed as % -+ S.E. of the blood glucose levels 
measured immediately before treatment inindividual rats. All 
differences in values between free and liposome-associated 
proteins at 1,4 and 24 h (insulin) and 1 and 4 h (glucose 
oxidase) are statistically significant (P < 0.001-0.05). 
associated with negative and positive egg lecithin 
liposomes and negative results were obtained with 
intragastrically administered insulin (480 units/kg) free 
(fig. 1) or associated with identical liposomes. However, 
when glucose oxidase was given in association with 
phosphatidyl inositol iposomes, blood glucose levels 
were decreased considerably (70-73% of the values 
before treatment for at least 4 h thereafter, fig.l). 
Decrease in blood glucose (75-80% of the values before 
treatment) was also observed with insulin associated 
with phosphatidyl inositol iposomes but the effect was 
maintained for at least 24 h (fig. 1). Phosphatidyl 
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